NO934801L - CTL4A reseptor, fusjonsproteiner som inneholder den og anvendelse derav - Google Patents
CTL4A reseptor, fusjonsproteiner som inneholder den og anvendelse deravInfo
- Publication number
- NO934801L NO934801L NO934801A NO934801A NO934801L NO 934801 L NO934801 L NO 934801L NO 934801 A NO934801 A NO 934801A NO 934801 A NO934801 A NO 934801A NO 934801 L NO934801 L NO 934801L
- Authority
- NO
- Norway
- Prior art keywords
- ctla4
- fusion proteins
- receptor
- proteins containing
- interactions
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70521—CD28, CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/866—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving immunoglobulin or antibody fragment, e.g. fab', fab, fv, fc, heavy chain or light chain
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/868—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, or immunotolerance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Virology (AREA)
- Gastroenterology & Hepatology (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pain & Pain Management (AREA)
- Physics & Mathematics (AREA)
- AIDS & HIV (AREA)
- Pulmonology (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Transplantation (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US72361791A | 1991-06-27 | 1991-06-27 | |
PCT/US1992/005202 WO1993000431A1 (en) | 1991-06-27 | 1992-06-16 | Ctl4a receptor, fusion proteins containing it and uses thereof |
Publications (3)
Publication Number | Publication Date |
---|---|
NO934801D0 NO934801D0 (no) | 1993-12-23 |
NO934801L true NO934801L (no) | 1994-02-21 |
NO312465B1 NO312465B1 (no) | 2002-05-13 |
Family
ID=24907003
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO19934801A NO312465B1 (no) | 1991-06-27 | 1993-12-23 | CTL4A reseptorprotein, DNA fusjonsproteiner og anvendelse derav samt in vitro fremgangsmåte, monoklonealt antistoff,kinesisk hamster-ovariecellelinje og farmasöytisk preparat |
NO20020491A NO318806B1 (no) | 1991-06-27 | 2002-01-30 | Opploselig CTLA4-molekyl, CTLA4Ig-fusjonsprotein, anvendelse og fremgangsmate for fremstilling derav samt farmasoytisk sammensetning, isolert nukleinsyremolekyl, plasmid, vertsvektorsystem, monoklonalt antistoff og in vitro fremgangsmate for regulering av funksjonelle CTLA4 positive T-celle interaksjoner med B7 positive celler. |
NO2007013C NO2007013I2 (no) | 1991-06-27 | 2007-11-14 | CTL4A reseptorprotein, DNA fusjonsproteiner og anvendelse derav samt in vitro fremgangsmåte, monoklonealt antistoff, kinesisk hamsterovariecellelinje og farmasøytisk preparat. |
NO2012001C NO2012001I2 (no) | 1991-06-27 | 2012-01-09 | Ipilimumab (INN) - krav I basispatent |
Family Applications After (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20020491A NO318806B1 (no) | 1991-06-27 | 2002-01-30 | Opploselig CTLA4-molekyl, CTLA4Ig-fusjonsprotein, anvendelse og fremgangsmate for fremstilling derav samt farmasoytisk sammensetning, isolert nukleinsyremolekyl, plasmid, vertsvektorsystem, monoklonalt antistoff og in vitro fremgangsmate for regulering av funksjonelle CTLA4 positive T-celle interaksjoner med B7 positive celler. |
NO2007013C NO2007013I2 (no) | 1991-06-27 | 2007-11-14 | CTL4A reseptorprotein, DNA fusjonsproteiner og anvendelse derav samt in vitro fremgangsmåte, monoklonealt antistoff, kinesisk hamsterovariecellelinje og farmasøytisk preparat. |
NO2012001C NO2012001I2 (no) | 1991-06-27 | 2012-01-09 | Ipilimumab (INN) - krav I basispatent |
Country Status (21)
Country | Link |
---|---|
US (1) | US5434131A (no) |
EP (1) | EP0606217B2 (no) |
JP (6) | JP3722375B2 (no) |
KR (1) | KR100238712B1 (no) |
AT (1) | ATE170562T1 (no) |
AU (1) | AU661854B2 (no) |
CA (2) | CA2110518C (no) |
DE (2) | DE69226871T3 (no) |
DK (1) | DK0606217T4 (no) |
ES (1) | ES2123001T5 (no) |
FI (2) | FI112082B (no) |
IE (2) | IE20010097A1 (no) |
IL (4) | IL159364A (no) |
LU (1) | LU91375I2 (no) |
MX (1) | MX9203605A (no) |
NL (1) | NL300303I1 (no) |
NO (4) | NO312465B1 (no) |
NZ (2) | NZ264712A (no) |
PT (1) | PT100637B (no) |
WO (1) | WO1993000431A1 (no) |
ZA (1) | ZA924782B (no) |
Families Citing this family (193)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL92382A (en) * | 1988-11-23 | 1994-12-29 | Univ Michigan | Use of a ligand specific for CD28 in the manufacture of medicament |
US6685941B1 (en) * | 1988-11-23 | 2004-02-03 | The Regents Of The University Of Michigan | Methods of treating autoimmune disease via CTLA-4Ig |
DE69032484D1 (de) * | 1989-10-27 | 1998-08-20 | Arch Dev Corp | Zusammensetzungen und deren verwendung zur förderung der immunopotentiation |
US6406696B1 (en) | 1989-10-27 | 2002-06-18 | Tolerance Therapeutics, Inc. | Methods of stimulating the immune system with anti-CD3 antibodies |
US5770197A (en) * | 1991-06-27 | 1998-06-23 | Bristol-Myers Squibb Company | Methods for regulating the immune response using B7 binding molecules and IL4-binding molecules |
US6090914A (en) * | 1991-06-27 | 2000-07-18 | Bristol-Myers Squibb Company | CTLA4/CD28Ig hybrid fusion proteins and uses thereof |
US6887471B1 (en) | 1991-06-27 | 2005-05-03 | Bristol-Myers Squibb Company | Method to inhibit T cell interactions with soluble B7 |
US5851795A (en) * | 1991-06-27 | 1998-12-22 | Bristol-Myers Squibb Company | Soluble CTLA4 molecules and uses thereof |
US5637481A (en) * | 1993-02-01 | 1997-06-10 | Bristol-Myers Squibb Company | Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell |
US5962406A (en) * | 1991-10-25 | 1999-10-05 | Immunex Corporation | Recombinant soluble CD40 ligand polypeptide and pharmaceutical composition containing the same |
US6472510B1 (en) * | 1992-02-14 | 2002-10-29 | Bristol-Myers Squibb Company | CD40 receptor ligands |
IL104684A0 (en) * | 1992-02-14 | 1993-06-10 | Bristol Myers Squibb Co | The cd40cr receptor and ligands therefor |
EP0637963B1 (en) * | 1992-04-07 | 2004-08-04 | The Regents of the University of Michigan | Cd28 pathway immunoregulation |
US5397703A (en) * | 1992-07-09 | 1995-03-14 | Cetus Oncology Corporation | Method for generation of antibodies to cell surface molecules |
US5747034A (en) * | 1992-07-09 | 1998-05-05 | Chiron Corporation | Methods and materials for the induction of T cell anergy |
US5773253A (en) * | 1993-01-22 | 1998-06-30 | Bristol-Myers Squibb Company | MYPPPY variants of CTL A4 and uses thereof |
US6491916B1 (en) | 1994-06-01 | 2002-12-10 | Tolerance Therapeutics, Inc. | Methods and materials for modulation of the immunosuppresive activity and toxicity of monoclonal antibodies |
US6024957A (en) * | 1993-06-02 | 2000-02-15 | Research Corporation Technologies, Inc. | Immunomodulators and methods for the prevention and reversal of organ transplant rejection using same |
US6106834A (en) | 1993-06-02 | 2000-08-22 | Research Corporation Technologies, Inc. | Use of anti-CD45 leukocyte antigen antibodies for immunomodulation |
CA2144319A1 (en) * | 1993-07-09 | 1995-01-19 | George N. Cox | Recombinant ctla4 polypeptides and methods for making the same |
US6084067A (en) | 1993-07-26 | 2000-07-04 | Dana-Farber Cancer Institute | CTLA4/CD28 ligands and uses therefor |
US6723705B1 (en) | 1993-08-19 | 2004-04-20 | Gentics Institute, Inc. | Tumor cells modified to express B7-2 with increased immunogenicity and uses therefor |
US6824779B1 (en) | 1993-07-26 | 2004-11-30 | Dana-Farber Cancer Institute, Inc. | Methods for inhibiting the interaction of B7-2 with its natural ligand |
US20050129670A1 (en) * | 1993-07-26 | 2005-06-16 | Genetics Institute, Llc. | Tumor cells modified to express B7-2 with increased immunogenicity and uses therefor |
US6130316A (en) * | 1993-07-26 | 2000-10-10 | Dana Farber Cancer Institute | Fusion proteins of novel CTLA4/CD28 ligands and uses therefore |
AU7405294A (en) | 1993-07-26 | 1995-02-20 | Dana-Farber Cancer Institute | B7-2: ctl a4/cd 28 counter receptor |
US5861310A (en) * | 1993-11-03 | 1999-01-19 | Dana-Farber Cancer Institute | Tumor cells modified to express B7-2 with increased immunogenicity and uses therefor |
WO1995005464A1 (en) * | 1993-08-16 | 1995-02-23 | Arch Development Corporation | B7-2: ctla4/cd28 counter receptor |
AU7638894A (en) * | 1993-09-03 | 1995-03-22 | Miyuki Azuma | B70(b7-2):ctla-4 bonding protein |
AU784510B2 (en) * | 1994-03-08 | 2006-04-13 | Dana-Farber Cancer Institute, Inc. | Methods for modulating T cell unresponsiveness |
EP0749323B1 (en) * | 1994-03-08 | 2000-11-29 | Dana-Farber Cancer Institute | Methods for modulating t cell anergy |
US6719972B1 (en) | 1994-06-03 | 2004-04-13 | Repligen Corporation | Methods of inhibiting T cell proliferation or IL-2 accumulation with CTLA4- specific antibodies |
CA2204183A1 (en) * | 1994-11-01 | 1996-05-09 | Andrew Lawrence Feldhaus | Chimeric receptors for the generation of selectively-activatable th-independent cytotoxic t cells |
US5576423A (en) | 1994-12-02 | 1996-11-19 | Schering Corporation | Antibodies to the slam protein expressed on activated T cells |
ATE384127T1 (de) | 1994-12-02 | 2008-02-15 | Schering Corp | Kostimulatorisches t-zell-oberflächen-antigen slam |
US6251957B1 (en) | 1995-02-24 | 2001-06-26 | Trustees Of The University Of Pennsylvania | Method of reducing an immune response to a recombinant virus |
US6372208B1 (en) | 1999-09-28 | 2002-04-16 | The Trustees Of The University Of Pennsylvania | Method of reducing an immune response to a recombinant virus |
US5652224A (en) * | 1995-02-24 | 1997-07-29 | The Trustees Of The University Of Pennsylvania | Methods and compositions for gene therapy for the treatment of defects in lipoprotein metabolism |
US5872154A (en) * | 1995-02-24 | 1999-02-16 | The Trustees Of The University Of Pennsylvania | Method of reducing an immune response to a recombinant adenovirus |
WO1996031229A1 (en) * | 1995-04-05 | 1996-10-10 | Beth Israel Hospital Association | Inhibiting rejection of a graft |
US7175847B1 (en) * | 1995-06-07 | 2007-02-13 | Biogen Idec Inc. | Treating intestinal inflammation with anti-CD80 antibodies that do not inhibit CD80 binding to CTLA-4 |
US6113898A (en) * | 1995-06-07 | 2000-09-05 | Idec Pharmaceuticals Corporation | Human B7.1-specific primatized antibodies and transfectomas expressing said antibodies |
US7153508B2 (en) * | 1995-06-07 | 2006-12-26 | Biogen Idec Inc. | Treatment of B cell lymphoma using anti-CD80 antibodies that do not inhibit the binding of CD80 to CTLA-4 |
US5811097A (en) * | 1995-07-25 | 1998-09-22 | The Regents Of The University Of California | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
US5855887A (en) * | 1995-07-25 | 1999-01-05 | The Regents Of The University Of California | Blockade of lymphocyte down-regulation associated with CTLA-4 signaling |
US6051227A (en) | 1995-07-25 | 2000-04-18 | The Regents Of The University Of California, Office Of Technology Transfer | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
US7041634B2 (en) | 1995-09-27 | 2006-05-09 | Emory University | Method of inhibiting immune system destruction of transplanted viable cells |
US6750334B1 (en) | 1996-02-02 | 2004-06-15 | Repligen Corporation | CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor |
US6107056A (en) * | 1996-02-22 | 2000-08-22 | Oaks; Martin K. | SCTLA-4 gene and product |
EP0892643B2 (en) * | 1996-03-20 | 2009-09-02 | Bristol-Myers Squibb Company | Methods for inhibiting an immune response by blocking the gp39/cd40 and ctla4/cd28/b7 pathways and compositions for use therewith |
US5786152A (en) * | 1996-04-26 | 1998-07-28 | Amgen Inc. | Methods of inhibiting syp binding to a CTLA-4 receptor |
WO1998019706A1 (en) * | 1996-11-08 | 1998-05-14 | Idec Pharmaceuticals Corporation | Identification of unique binding interactions between certain antibodies and the human b7.1 and b7.2 co-stimulatory antigens |
US20060034844A1 (en) * | 1996-12-04 | 2006-02-16 | The Regents Of The University Of California | Stimulation of T cells against self antigens using CTLA-4 blocking agents |
US20040023917A1 (en) * | 1996-12-31 | 2004-02-05 | Bennett C. Frank | Oligonucleotide compositions and methods for the modulation of the expression of B7 protein |
US6077833A (en) * | 1996-12-31 | 2000-06-20 | Isis Pharmaceuticals, Inc. | Oligonucleotide compositions and methods for the modulation of the expression of B7 protein |
US6319906B1 (en) | 1996-12-31 | 2001-11-20 | Isis Pharmaceuticals | Oligonucleotide compositions and methods for the modulation of the expression of B7 protein |
US7235653B2 (en) * | 1996-12-31 | 2007-06-26 | Isis Pharmaceuticals, Inc. | Oligonucleotide compositions and methods for the modulation of the expression of B7 protein |
KR19980066046A (ko) * | 1997-01-18 | 1998-10-15 | 정용훈 | 고역가의 CTLA4-Ig 융합단백질 |
ZA98533B (en) * | 1997-01-31 | 1999-07-22 | Bristol Myers Squibb Co | Soluble CTLA4 mutant molecules and uses thereof. |
US20030219863A1 (en) * | 1997-01-31 | 2003-11-27 | Bristol-Myers Squibb Company | Soluble CTLA4 mutant molecules and uses thereof |
WO1998042752A1 (en) | 1997-03-21 | 1998-10-01 | Brigham And Women's Hospital Inc. | Immunotherapeutic ctla-4 binding peptides |
SE9701127D0 (sv) * | 1997-03-26 | 1997-03-26 | Karolinska Innovations Ab | Antigenic fusionprotein carrying GALal, 3GAL epitopes |
WO1998044129A1 (en) * | 1997-03-27 | 1998-10-08 | The Council Of The Queensland Institute Of Medical Research | Enhancement of immune response using targeting molecules |
JP2001524824A (ja) | 1997-04-16 | 2001-12-04 | ミレニアム・フアーマシユーチカルズ・インコーポレーテツド | Crspタンパク質(システインに富む分泌性タンパク質)、それらをコードする核酸分子およびその用途 |
JP2002505673A (ja) | 1997-06-12 | 2002-02-19 | アプライド リサーチ システムズ エーアールエス ホールディング ナームロゼ フェンノートシャップ | Cd28/ctla−4阻害性ペプチド模倣物、それらの医薬組成物、およびそれらを使用する方法 |
WO1999015552A1 (fr) * | 1997-09-19 | 1999-04-01 | Yoshitomi Pharmaceutical Industries, Ltd. | Composes oligopeptidiques |
ATE319825T1 (de) | 1997-11-07 | 2006-03-15 | Trillium Therapeutics Inc | Verfahren und zusammensetzungen zur immunomodulation |
US6955811B2 (en) * | 1997-11-07 | 2005-10-18 | Trillium Therapeutics Inc. | Methods of inhibiting immune response suppression by administering antibodies to OX-2 |
US7223729B2 (en) * | 1997-11-07 | 2007-05-29 | Trillium Therapeutics Inc. | Methods of treating allergy by administering a CD200 protein |
AUPP221098A0 (en) | 1998-03-06 | 1998-04-02 | Diatech Pty Ltd | V-like domain binding molecules |
CA2328725A1 (en) * | 1998-04-15 | 1999-10-21 | Brigham & Women's Hospital, Inc. | T cell inhibitory receptor compositions and uses thereof |
US7279168B2 (en) | 1998-05-01 | 2007-10-09 | Texas A & M University System | Recombinant virus expressing foreign DNA encoding feline CD86 and uses thereof |
US7078512B2 (en) | 1998-05-01 | 2006-07-18 | Schering-Plough Animal Health Corporation | Nucleic acid encoding feline CD86 |
US20050031611A1 (en) * | 1998-05-08 | 2005-02-10 | Beth Israel Deaconess Medical Center | Transplant tolerance by costimulation blockade and T-cell activation-induced apoptosis |
US6682741B1 (en) * | 1998-06-10 | 2004-01-27 | The United States Of America As Represented By The Department Of Health And Human Services | β2 microglobulin fusion proteins and high affinity variants |
EP1088084B1 (en) * | 1998-06-15 | 2006-09-13 | GTC Biotherapeutics, Inc. | Erythropoietin analog-human serum albumin fusion protein |
US20050181482A1 (en) * | 2004-02-12 | 2005-08-18 | Meade Harry M. | Method for the production of an erythropoietin analog-human IgG fusion proteins in transgenic mammal milk |
US6593133B1 (en) | 1998-07-06 | 2003-07-15 | Nsgene A/S | Neurotrophic factors |
CA2343916A1 (en) | 1998-09-21 | 2000-03-30 | Genetics Institute, Inc. | Methods of downmodulating the immune response to therapeutic proteins |
US6521419B1 (en) | 1998-09-22 | 2003-02-18 | Kanakaraju Koduri | Expression vectors containing hot spot for increased recombinant protein expression in transfected cells |
US6800457B2 (en) | 1998-09-22 | 2004-10-05 | Bristol-Myers Squibb Company | Expression vectors containing hot spot for increased recombinant protein expression in transfected cells |
US7109003B2 (en) | 1998-12-23 | 2006-09-19 | Abgenix, Inc. | Methods for expressing and recovering human monoclonal antibodies to CTLA-4 |
EE05627B1 (et) | 1998-12-23 | 2013-02-15 | Pfizer Inc. | CTLA-4 vastased inimese monoklonaalsed antikehad |
CZ302706B6 (cs) * | 1998-12-23 | 2011-09-14 | Pfizer Inc. | Lidská monoklonální protilátka, farmaceutická kompozice tuto protilátku obsahující, bunecná linie produkující tuto protilátku, izolovaná molekula kódující težký nebo lehký retezec uvedené protilátky, hostitelská bunka obsahující tuto izolovanou molek |
US7011833B1 (en) | 1999-05-06 | 2006-03-14 | Genetics Institute, Inc. | Enhancing immune responses with B7-1 or B7-2 in the absence of a crosslinking agent |
WO2001008700A1 (en) * | 1999-07-28 | 2001-02-08 | Genetics Institute, Inc. | Preventing immune-mediated abortion by inhibiting costimulation |
US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
MXPA02001911A (es) | 1999-08-24 | 2003-07-21 | Medarex Inc | Anticuerpos ctla-4 humanos y sus usos. |
DE60127933T2 (de) * | 2000-01-03 | 2008-02-07 | Mark L. Merion Station Tykocinski | Chimäre proteine und anwendungen |
US7572631B2 (en) * | 2000-02-24 | 2009-08-11 | Invitrogen Corporation | Activation and expansion of T cells |
US7541184B2 (en) | 2000-02-24 | 2009-06-02 | Invitrogen Corporation | Activation and expansion of cells |
KR100889887B1 (ko) * | 2000-05-26 | 2009-03-24 | 브리스톨-마이어스스퀴브컴파니 | 가용성 ctla4 돌연변이 분자 및 그의 용도 |
US7094874B2 (en) | 2000-05-26 | 2006-08-22 | Bristol-Myers Squibb Co. | Soluble CTLA4 mutant molecules |
CA2411962A1 (en) * | 2000-06-09 | 2001-12-20 | Bristol-Myers Squibb Company | Methods for regulating a cell-mediated immune response by blockinglymphocytic signals and by blocking lfa-1 mediated adhesion |
US20040034193A1 (en) * | 2001-06-13 | 2004-02-19 | Samy Ashkar | Biosynthetic oncolytic molecules and uses therefor |
US20050048614A1 (en) * | 2000-06-13 | 2005-03-03 | Children's Medical Center Corporation | Biosynthetic oncolytic molecules and uses therefor |
TR201807700T4 (tr) | 2000-07-03 | 2018-06-21 | Squibb Bristol Myers Co | Çözünür CTLA4 mutant moleküllerinin kullanımları. |
US20040022787A1 (en) | 2000-07-03 | 2004-02-05 | Robert Cohen | Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID |
US6875904B2 (en) * | 2000-09-20 | 2005-04-05 | The Ohio State University Research Foundation | Animal model for identifying agents that inhibit or enhance CTLA4 signaling |
US7014998B2 (en) * | 2000-09-30 | 2006-03-21 | Yale University | Screening immunomodulatory agents by CTLA-4 upregulation |
US20040198661A1 (en) * | 2000-12-08 | 2004-10-07 | Bowdish Katherine S. | Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof |
US7408041B2 (en) * | 2000-12-08 | 2008-08-05 | Alexion Pharmaceuticals, Inc. | Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof |
US9249229B2 (en) * | 2000-12-08 | 2016-02-02 | Alexion Pharmaceuticals, Inc. | Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof |
WO2002059280A2 (en) * | 2000-12-08 | 2002-08-01 | Alexion Pharmaceuticals, Inc. | Chronic lymphocytic leukemia cell line and its use for producing an antibody |
US20060057651A1 (en) * | 2000-12-08 | 2006-03-16 | Bowdish Katherine S | Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof |
US7754208B2 (en) * | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
US7829084B2 (en) * | 2001-01-17 | 2010-11-09 | Trubion Pharmaceuticals, Inc. | Binding constructs and methods for use thereof |
US20030133939A1 (en) * | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
HUP0303930A3 (en) * | 2001-01-26 | 2012-09-28 | Univ Emory | Methods of inducing organ transplant tolerance and correcting hemoglobinopathies |
TW200526779A (en) * | 2001-02-08 | 2005-08-16 | Wyeth Corp | Modified and stabilized GDF propeptides and uses thereof |
AU2002250203B2 (en) | 2001-03-28 | 2006-08-10 | Biogen Ma Inc. | Use of neublastin polypeptides for treating neuropathic pain |
US20040058445A1 (en) * | 2001-04-26 | 2004-03-25 | Ledbetter Jeffrey Alan | Activation of tumor-reactive lymphocytes via antibodies or genes recognizing CD3 or 4-1BB |
DE60225914T2 (de) | 2001-05-23 | 2009-07-23 | Bristol-Myers Squibb Co. | Verfahren zum schützen eines allogenen inseltransplantats mit löslichen ctla4-mutationsmolekülen |
KR100453877B1 (ko) | 2001-07-26 | 2004-10-20 | 메덱스젠 주식회사 | 연쇄체화에 의한 면역 글로블린 융합 단백질의 제조 방법 및 이 방법에 의해 제조된 TNFR/Fc 융합 단백질, 상기 단백질을 코딩하는 DNA, 상기 DNA를 포함하는벡터, 및 상기 벡터에 의한 형질전환체 |
US20030086940A1 (en) * | 2001-08-10 | 2003-05-08 | Cristina Costa | Engineered recombinant molecule that regulates humoral and cellular effector functions of the immune system |
US20040116675A1 (en) * | 2001-12-14 | 2004-06-17 | Tso J. Jun | Silenced anti-cd28 antibodies and use thereof |
AU2002361385B2 (en) * | 2001-12-18 | 2009-11-19 | Centre National De La Recherche Scientifique Cnrs | Novel death associated proteins of the THAP family and related Par4 pathways involved in apoptosis control |
US7858297B2 (en) * | 2001-12-18 | 2010-12-28 | Centre National De La Recherche Scientifique Cnrs | Chemokine-binding protein and methods of use |
US6578724B1 (en) * | 2001-12-29 | 2003-06-17 | United States Can Company | Connector for use in packaging aerosol containers |
EP2138575B8 (en) | 2002-02-20 | 2013-07-24 | Mersana Therapeutics, Inc. | Conjugates comprising a biodegradable polymer and uses therefor |
US20030219436A1 (en) * | 2002-03-15 | 2003-11-27 | Ledbetter Jeffrey A. | Compositions and methods to regulate an immune response using CD83 gene expressed in tumors and using soluble CD83-Ig fusion protein |
JP2005529873A (ja) | 2002-04-12 | 2005-10-06 | メダレックス インコーポレイテッド | Ctla−4抗体を使用した治療の方法 |
RU2375077C2 (ru) * | 2002-05-02 | 2009-12-10 | Юниверсити Оф Коннектикут Хелт Сентер | Использование белков теплового шока для повышения эффективности терапий антителами |
US20040247578A1 (en) * | 2002-10-15 | 2004-12-09 | University Of Pittsburgh Of Commonwealth System Of Higher Education | Methods and reagents for inducing immunity |
CN100402660C (zh) * | 2002-12-23 | 2008-07-16 | 布里斯托尔-迈尔斯斯奎布公司 | 用于蛋白质生产的哺乳动物细胞培养方法中产物质量提高 |
TWI312368B (en) * | 2002-12-23 | 2009-07-21 | Bristol Myers Squibb Compan | Mammalian cell culture processes for protein production |
PL383683A1 (pl) | 2003-01-31 | 2008-04-14 | Biogen Idec Ma Inc. | Koniugaty polimerowe zmutowanej neublastyny |
GB0303663D0 (en) * | 2003-02-18 | 2003-03-19 | Lorantis Ltd | Assays and medical treatments |
US7897582B2 (en) * | 2003-05-23 | 2011-03-01 | Isis Pharmaceuticals, Inc. | Oligonucleotide compositions and methods for the modulation of the expression of B7 protein |
US7960355B2 (en) * | 2003-05-23 | 2011-06-14 | Isis Pharmaceuticals, Inc. | Compositions and methods for the modulation of the expression of B7 protein |
US6971600B2 (en) * | 2003-06-30 | 2005-12-06 | Heligear Engineering (H.K.) Co., Ltd. | Oscillation mechanism for fishing reel |
US7754209B2 (en) | 2003-07-26 | 2010-07-13 | Trubion Pharmaceuticals | Binding constructs and methods for use thereof |
WO2005016266A2 (en) * | 2003-08-04 | 2005-02-24 | Bristol-Myers Squibb Company | Methods for treating cardiovascular disease using a soluble ctla4 molecule |
AU2004287431B2 (en) * | 2003-10-27 | 2010-03-11 | Amgen Inc. | Compositions and methods to modulate an immune response to an immunogenic therapeutic agent |
WO2006029219A2 (en) * | 2004-09-08 | 2006-03-16 | Ohio State University Research Foundation | Human monoclonal anti-ctla4 antibodies in cancer treatment |
WO2006029220A2 (en) * | 2004-09-08 | 2006-03-16 | Ohio State University Research Foundation | Combination therapy with anti-ctla4 and anti-4-1bb antibodies |
GB0421465D0 (en) * | 2004-09-27 | 2004-10-27 | Chiron Srl | Group A streptococcus protein |
CA2603970A1 (en) * | 2005-04-06 | 2006-10-12 | Bristol-Myers Squibb Company | Methods for treating immune disorders associated with graft transplantation with soluble ctla4 mutant molecules |
US8663634B2 (en) | 2005-07-11 | 2014-03-04 | Macrogenics, Inc. | Methods for the treatment of autoimmune disorders using immunosuppressive monoclonal antibodies with reduced toxicity |
UA97469C2 (uk) | 2005-07-25 | 2012-02-27 | Емерджент Продакт Дівелопмент Сіетл, Елелсі | Гуманізована специфічна до cd37 зв'язувальна молекула імуноглобуліну |
JP4899083B2 (ja) * | 2005-08-29 | 2012-03-21 | Smc株式会社 | 減速比自動切換装置 |
AU2013202533B2 (en) * | 2005-11-08 | 2015-11-12 | Sarepta Therapeutics, Inc. | Immunosuppression Compound and Treatment Method |
WO2007056466A2 (en) * | 2005-11-08 | 2007-05-18 | Avi Biopharma, Inc. | Immunosuppression compound and treatment method |
US8501704B2 (en) | 2005-11-08 | 2013-08-06 | Sarepta Therapeutics, Inc. | Immunosuppression compound and treatment method |
JP2009518446A (ja) | 2005-12-07 | 2009-05-07 | メダレックス インコーポレーティッド | Ctla−4抗体投与量漸増レジメン |
ES2439641T3 (es) | 2005-12-20 | 2014-01-24 | Bristol-Myers Squibb Company | Composiciones y procedimientos de producción de una composición |
ES2586825T3 (es) | 2006-01-12 | 2016-10-19 | Alexion Pharmaceuticals, Inc. | Anticuerpos para OX-2/CD200 y usos de los mismos |
CA2646329C (en) | 2006-03-20 | 2018-07-03 | The Regents Of The University Of California | Engineered anti-prostate stem cell antigen (psca) antibodies for cancer targeting |
US7528111B2 (en) * | 2006-05-12 | 2009-05-05 | Bristol-Myers Squibb Company | Method of vaccinating subjects receiving immune modulating therapy |
NZ573646A (en) | 2006-06-12 | 2012-04-27 | Wyeth Llc | Single-chain multivalent binding proteins with effector function |
SG10201504662WA (en) | 2006-06-14 | 2015-07-30 | Macrogenics Inc | Methods For The Treatment Of Autoimmune Disorders Using Immunosuppressive Monoclonal Antibodies With Reduced Toxicity |
BRPI0814645A2 (pt) * | 2007-07-25 | 2015-01-27 | Alexion Pharma Inc | Métodos e composições para tratar de doença autoimune. |
US8940298B2 (en) | 2007-09-04 | 2015-01-27 | The Regents Of The University Of California | High affinity anti-prostate stem cell antigen (PSCA) antibodies for cancer targeting and detection |
EP2612868B1 (en) | 2007-11-01 | 2018-08-15 | Astellas Pharma Inc. | Immunosuppressive polypeptides and nucleic acids |
NZ603059A (en) | 2008-04-11 | 2014-07-25 | Emergent Product Dev Seattle | Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof |
US7915222B2 (en) * | 2008-05-05 | 2011-03-29 | Bristol-Myers Squibb Company | Method of preventing the development of rheumatoid arthritis in subjects with undifferentiated arthritis |
MX338825B (es) | 2008-10-02 | 2016-05-03 | Emergent Product Dev Seattle | Proteinas de enlace a objetivos multiples de antagonistas de cd86. |
KR20110083730A (ko) * | 2008-11-13 | 2011-07-20 | 이머전트 프로덕트 디벨롭먼트 시애틀, 엘엘씨 | Cd37 면역치료제 병용 요법 및 이의 용도 |
EP3381937A3 (en) * | 2009-08-13 | 2018-10-31 | The Johns Hopkins University | Methods of modulating immune function |
US9540426B2 (en) | 2009-10-06 | 2017-01-10 | Bristol-Myers Squibb Company | Mammalian cell culture processes for protein production |
WO2011045704A1 (en) | 2009-10-12 | 2011-04-21 | Pfizer Inc. | Cancer treatment |
CN106432474A (zh) | 2010-03-12 | 2017-02-22 | 艾伯维生物医疗股份有限公司 | Ctla4蛋白和其用途 |
CN103153332A (zh) | 2010-09-28 | 2013-06-12 | 卡尔医疗有限公司 | 用于治疗血液恶性肿瘤的组合物和方法 |
WO2013010537A1 (en) | 2011-07-20 | 2013-01-24 | Aarhus Universitet | Method of treating morphea |
US9758566B2 (en) | 2012-03-29 | 2017-09-12 | The General Hospital Corporation | Recombinant cytotoxic T-lymphocyte-associated protein 4 (CTLA4) |
US20150118244A1 (en) | 2012-05-10 | 2015-04-30 | Bristol-Myers Squibb Company | Anti-tumor antibodies as predictive or prognostic biomarkers of efficacy and survival in ipilimumab-treated patients |
ES2777778T3 (es) | 2012-05-11 | 2020-08-06 | Medimmune Ltd | Variantes de CTLA-4 |
US8735359B2 (en) | 2012-05-24 | 2014-05-27 | Orban Biotech Llc | Combinations of modalities for the treatment of diabetes |
CA2877986A1 (en) | 2012-06-27 | 2014-01-03 | Orban Biotech Llc | Ctla4 fusion proteins for the treatment of diabetes |
US20140112958A1 (en) | 2012-10-24 | 2014-04-24 | Mwm Biomodels Gmbh | Pancreatic islets of transgenic LEA29Y animals for treating diabetes |
US9944689B2 (en) | 2013-03-07 | 2018-04-17 | The General Hospital Corporation | Human CTLA4 mutants and use thereof |
US10570204B2 (en) | 2013-09-26 | 2020-02-25 | The Medical College Of Wisconsin, Inc. | Methods for treating hematologic cancers |
EP2883883A1 (en) | 2013-12-16 | 2015-06-17 | Cardio3 Biosciences S.A. | Therapeutic targets and agents useful in treating ischemia reperfusion injury |
JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
JOP20200096A1 (ar) | 2014-01-31 | 2017-06-16 | Children’S Medical Center Corp | جزيئات جسم مضاد لـ tim-3 واستخداماتها |
GB2523399B (en) | 2014-02-25 | 2019-03-13 | Orban Tihamer | A composition comprising ten overlapping peptide fragments of the entire preproinsulin sequence |
EP3925622A1 (en) | 2014-09-13 | 2021-12-22 | Novartis AG | Combination therapies |
PT3240801T (pt) | 2014-12-31 | 2021-02-18 | Checkmate Pharmaceuticals Inc | Imunoterapia antitumoral combinada |
DK3283508T3 (en) | 2015-04-17 | 2021-05-31 | Alpine Immune Sciences Inc | Immunomodulatory Proteins with Tunable Affinities |
US11352426B2 (en) | 2015-09-21 | 2022-06-07 | Aptevo Research And Development Llc | CD3 binding polypeptides |
EP3192805A1 (en) | 2016-01-15 | 2017-07-19 | Humanitas Mirasole S.p.A. | Inhibitors of t cell activation or stimulation and uses thereof |
MX2019009660A (es) | 2017-02-28 | 2019-10-02 | Bristol Myers Squibb Co | Uso de anticuerpos antigeno 4 del linfocito t (ctla-4) con citotoxicidad celular dependiente de anticuerpos (adcc) mejorada para mejorar la respuesta inmune a una vacuna. |
WO2018187227A1 (en) | 2017-04-03 | 2018-10-11 | Concologie, Inc. | Methods for treating cancer using ps-targeting antibodies with immuno-oncology agents |
WO2019067499A1 (en) | 2017-09-27 | 2019-04-04 | Alexion Pharmaceuticals, Inc. | BIOMARKER SIGNATURE FOR PREDICTING A TUMOR RESPONSE TO ANTI-CD200 THERAPY |
CA3077509A1 (en) | 2017-10-10 | 2019-04-18 | Alpine Immune Sciences, Inc. | Ctla-4 variant immunomodulatory proteins and uses thereof |
EP3617230A1 (en) | 2018-09-03 | 2020-03-04 | BioInvent International AB | Novel antibodies and nucleotide sequences, and uses thereof |
WO2020112904A1 (en) | 2018-11-26 | 2020-06-04 | Massachusetts Institute Of Technology | Compositions and methods for immune tolerance |
CN114981659A (zh) | 2019-11-21 | 2022-08-30 | 百时美施贵宝公司 | 无标记n-聚糖定量方法 |
CA3207134A1 (en) | 2021-02-19 | 2022-08-25 | Jeffrey A. Ledbetter | Dnase fusion polypeptides and related compositions and methods |
GB202115803D0 (en) | 2021-11-03 | 2021-12-15 | Ducentis Biotherapeutics Ltd | Novel proteins |
WO2023214388A1 (en) | 2022-05-06 | 2023-11-09 | Ducentis Biotherapeutics Limited | Novel cd200 fusion proteins |
WO2023214387A1 (en) | 2022-05-06 | 2023-11-09 | Ducentis Biotherapeutics Limited | Novel cd200 fusion proteins |
CN114686427B (zh) * | 2022-05-23 | 2022-07-29 | 中国人民解放军总医院第一医学中心 | 一种脾脏调节型b淋巴细胞及其制备方法与应用 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4399216A (en) * | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4683195A (en) * | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
US4683202A (en) * | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
-
1992
- 1992-06-16 DE DE69226871T patent/DE69226871T3/de not_active Expired - Lifetime
- 1992-06-16 DK DK92914009T patent/DK0606217T4/da active
- 1992-06-16 ES ES92914009T patent/ES2123001T5/es not_active Expired - Lifetime
- 1992-06-16 CA CA002110518A patent/CA2110518C/en not_active Expired - Lifetime
- 1992-06-16 JP JP50156993A patent/JP3722375B2/ja not_active Expired - Lifetime
- 1992-06-16 CA CA002580812A patent/CA2580812A1/en not_active Abandoned
- 1992-06-16 WO PCT/US1992/005202 patent/WO1993000431A1/en active IP Right Grant
- 1992-06-16 KR KR1019930703876A patent/KR100238712B1/ko not_active IP Right Cessation
- 1992-06-16 EP EP92914009A patent/EP0606217B2/en not_active Expired - Lifetime
- 1992-06-16 AU AU22400/92A patent/AU661854B2/en not_active Expired
- 1992-06-16 AT AT92914009T patent/ATE170562T1/de active
- 1992-06-16 DE DE122007000078C patent/DE122007000078I2/de active Active
- 1992-06-24 NZ NZ264712A patent/NZ264712A/en not_active IP Right Cessation
- 1992-06-24 IL IL15936492A patent/IL159364A/xx not_active IP Right Cessation
- 1992-06-24 NZ NZ243286A patent/NZ243286A/en not_active IP Right Cessation
- 1992-06-24 IL IL10229492A patent/IL102294A/en not_active IP Right Cessation
- 1992-06-26 PT PT100637A patent/PT100637B/pt not_active IP Right Cessation
- 1992-06-26 ZA ZA924782A patent/ZA924782B/xx unknown
- 1992-06-26 MX MX9203605A patent/MX9203605A/es active IP Right Grant
- 1992-07-01 IE IE20010097A patent/IE20010097A1/en not_active IP Right Cessation
- 1992-07-01 IE IE211192A patent/IE922111A1/en not_active IP Right Cessation
-
1993
- 1993-05-26 US US08/067,684 patent/US5434131A/en not_active Expired - Lifetime
- 1993-12-22 FI FI935795A patent/FI112082B/fi not_active IP Right Cessation
- 1993-12-23 NO NO19934801A patent/NO312465B1/no not_active IP Right Cessation
-
2001
- 2001-05-07 JP JP2001136657A patent/JP4159266B2/ja not_active Expired - Lifetime
- 2001-05-07 JP JP2001136664A patent/JP2002003399A/ja not_active Withdrawn
-
2002
- 2002-01-30 NO NO20020491A patent/NO318806B1/no not_active IP Right Cessation
- 2002-04-11 JP JP2002109829A patent/JP2003012546A/ja not_active Withdrawn
- 2002-07-22 JP JP2002213195A patent/JP2003096097A/ja not_active Withdrawn
- 2002-10-01 JP JP2002289290A patent/JP2003174872A/ja active Pending
- 2002-12-30 FI FI20022285A patent/FI115057B/fi not_active IP Right Cessation
-
2003
- 2003-12-15 IL IL15936403A patent/IL159364A0/xx unknown
-
2004
- 2004-06-10 IL IL16243004A patent/IL162430A0/xx unknown
-
2007
- 2007-11-02 NL NL300303C patent/NL300303I1/nl unknown
- 2007-11-07 LU LU91375C patent/LU91375I2/fr unknown
- 2007-11-14 NO NO2007013C patent/NO2007013I2/no unknown
-
2012
- 2012-01-09 NO NO2012001C patent/NO2012001I2/no not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO934801L (no) | CTL4A reseptor, fusjonsproteiner som inneholder den og anvendelse derav | |
DK0613944T3 (da) | Fremgangsmåder til regulering af immunresponset under anvendelse af CTLA4-bindende molekyler og IL4-bindende molekyler | |
NO963018L (no) | CTLA4-mutantmolekyler og anvendelser derav | |
WO1996013593A3 (en) | Soluble single chain t cell receptors | |
UY25943A1 (es) | Proteínas de fusión ctla4 ig" para regular las interacciones celulares y las respuestas inmunitarias. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
SPCF | Filing of supplementary protection certificate |
Free format text: PRODUCT NAME: ABATACEPT; NAT. REG. NO/DATE: EU107389001/NO 20070619; FIRST REG. NO/DATE: GB , EU107389001-003 20070521 Spc suppl protection certif: 2007013 Filing date: 20071114 |
|
SPCG | Granted supplementary protection certificate |
Free format text: PRODUCT NAME: ABATACEPT; NAT. REG. NO/DATE: EU107389001/NO 20070619; FIRST REG. NO/DATE: GB , EU107389001-003 20070521 Spc suppl protection certif: 2007013 Filing date: 20071114 Extension date: 20170616 |
|
MK1K | Patent expired | ||
SPCX | Expiry of an spc |
Spc suppl protection certif: 2007013 Effective date: 20170616 |